Comparison Between Use of Oral Misoprostol Versus Vaginal Misoprostol for Induction of Labour at Term

Prameela¹ · Kavya D. Sharma¹

Received: 3 November 2016 / Accepted: 2 March 2017 / Published online: 26 April 2017
© Federation of Obstetric & Gynecological Societies of India 2017

About the Author

Dr. Prameela at present working as Professor and HOD, Department of OBG, Mysore Medical College and Research Institute, Mysore, Karnataka. She has a teaching experience of 22 years. She is a PG teacher since 2003. She was the president of Mysore Obstetrics and Gynecology Society and conducted many workshops in critical care in obstetrics, urogynaecology, and conducted many CME's. She presented many papers in state and national conferences and published seven original articles in national and international journals.

Abstract

Background and Objective In modern obstetrics, around 30% of cases require induction of labour for various reasons. Misoprostol is gaining popularity as pharmacological inducing agent, though the route and dosage of administration are not standardised. The objective of the study is to compare the safety and efficacy of the two routes of misoprostol administration—oral (100 µg 4th hourly) and vaginal (25 µg 4th hourly), for induction of labour at term.

Dr. Prameela is a Professor and HOD at Department of Obstetrics and Gynaecology in MMC & RI; Dr. Kavya D. Sharma as Postgraduate at Department of Obstetrics and Gynaecology in MMC & RI.

✉ Prameela
hjprameela@gmail.com

¹ Department of Obstetrics and Gynaecology, MMC & RI, Mysuru, India

Methods In this randomised trial, 104 women having crossed the expected date of delivery without going into spontaneous labour and cases which had premature rupture of membranes <12 h were considered for labour induction and were divided into two equal groups. Group A received 100 µg misoprostol orally 4th hourly, and group B received 25 µg misoprostol vaginally 4th hourly. Labour characteristics and maternal and foetal outcome were compared. **Results** In terms of maternal outcome, mean number of doses for oral group is 2.73 and vaginal group is 3.04. In oral group, mean induction to vaginal delivery interval was 13 h 43 min and in vaginal group interval is 13 h 26 min which was statistically not significant. The need for oxytocin augmentation was also statistically not significant. Both groups had equal number of failed inductions. Emergency LSCS done for foetal distress was more in vaginal group 2.9% compared to oral group which is 1%, but difference was not statistically significant (p value = 0.55). Number of thick MSL in oral group was 3.2% as

compared to vaginal group which is 10.7% which was statistically significant (p value = 0.04). APGAR score at 5 min 7/10 was seen in 7.7% in vaginal group as compared to 0% in oral group which was also statistically significant (0.004). Number of NICU admissions was also more in vaginal group compared to oral group.

Conclusion Misoprostol in either oral or vaginal route has proven to be equally effective for inducing labour in women at term pregnancy. However, occurrence of lesser incidence of meconium-stained liquor and NICU admissions and fewer caesareans with better neonatal outcome in women induced with oral misoprostol outweighs its advantages over the vaginal misoprostol.

Keywords Pregnancy · Misoprostol · Induction · NICU

Introduction

Induction of labour is a well-established obstetric concept since ancient times. Induction of labour is one of the most common procedures in obstetrics. In modern obstetrics, induction is indicated when benefits to either the mother and/or the foetus outweigh the risks in continuing the pregnancy. It could be elective or emergency induction of labour. In modern times, 10–33% obstetric cases require induction of labour.

Induction of labour is defined as iatrogenic stimulation of uterine contraction to accomplish delivery prior to the onset of spontaneous labour aimed at delivery by vaginal route [1, 2].

There are various methods of induction of labour falling in two broad categories: non-pharmacological and pharmacological. Amongst various methods used for ripening of cervix and induction of labour, prostaglandin E1 (misoprostol) is safe, reliable, cheap, easily applicable, and readily available, which results in good maternal and foetal outcome.

Prostaglandin E1 (misoprostol) tablets as an inducing agent of labour by various routes, e.g. vaginal, oral, and rectal, have received huge attention. The American College of Obstetricians and Gynaecologists (2000, 2003) has reaffirmed the use of misoprostol as a drug for induction of labour because of its proven safety and efficacy. This 'Off label' use of misoprostol has gained acceptance amongst international bodies of obstetricians. The ideal dose and route of administration are, however, still subject of debate.

Materials and Methods

A total of 104 women at term with indication of labour induction admitted in Cheluvamba hospital over a period of 1 year will be included in the study, from December

2013 to May 2015. Patients who receive 100 µg oral misoprostol will be considered as group A and those who receive 25 µg vaginal misoprostol will be considered as group B.

Inclusion Criteria

1. Live singleton pregnancy of gestational age of 37–42 weeks.
2. Nulliparous women.
3. A cephalic presentation.
4. Postdated pregnancy.
5. Premature rupture of membranes.
6. Bishop score <6.

Exclusion Criteria

1. Previous uterine scar.
2. CPD
3. Antepartum haemorrhage
4. Multiparity.
5. Multiple gestation.
6. Oligohydramnios
7. Polyhydramnios.
8. IUGR
9. Medical disorders like diabetes mellitus and hypertension
10. Contraindication to prostaglandins like asthma.
11. Preterm premature rupture of membranes.
12. History of glaucoma and epilepsy.

Investigation

Routine Investigations

Hb%, BT, CT, urine routine, blood group, random blood sugar, HIV, HbSAg, VDRL, ultrasonography if required

Method of Data Collection

A total of 104 women at term with indication of labour induction admitted in Cheluvamba hospital over a period of 1 year will be included in the study, from December 2013 to December 2014. It is a prospective randomised study. The patients were divided into two groups.

Group A: includes patients who received Tab. misoprostol 100 µg per orally every 4th hourly till maximum dosage of six doses.

Group B: includes patients who received Tab. misoprostol 25 µg per vaginally every 4th hourly till maximum of six doses.

Demographic details such as age, height, weight, parity, gestational age and indication for induction, and AFI are noted. Bishop's score before induction is assessed by per vaginal examination. After obtaining informed consent, they will be randomised to receive either 100 µg of oral or 25 µg of vaginal misoprostol. Before administration of drug, each woman will have a pelvic examination to assess the Bishop's score to rule out active labour.

The dose will be repeated every 4th hourly for a maximum of six doses for both groups A and B. The dose will be withheld in the presence of active labour, ≥ 3 contractions over 10 min or a cervical dilation of ≥ 4 cm. From the time of induction of labour to delivery, the patients were closely monitored for signs of labour, progress of labour, uterine contractions, and FHR monitored by intermittent auscultations. If the patient went into the active phase of labour, artificial rupture of membrane was done if required. In case of failure of induction, the patient was taken for LSCS directly.

Results

Data were entered in Excel format and analysed using EPI INFO software. Percentage and frequencies were calculated for categorical data, and Chi-square test was done to know association between groups A and B. Mean and standard deviations were calculated for continuous variables, and Student's *t* test was done to find association between two groups. *p* value ≤ 0.05 at 95% confidence interval was considered significant.

Majority of the women belonged to age group 21–25 years. Numbers of women in gestational age between 37 and 40 weeks are 41.3% out of which 19.2% belong to oral group and 22.1% belong to vaginal group. A total of 58.7% of women were above 40 weeks of gestation, out of which 30.8% of women belonged to oral group and 27.9% belonged to vaginal group. Indications for induction in both the groups were postdated and premature rupture of membranes.

For oral group, the mean pre-induction score was 2.98. For vaginal group, the mean pre-induction score was 2.52 (Fig. 1).

Mean number of doses for oral group is 2.73, and vaginal group is 3.04 with *p* value of 0.227 (Table 1; Fig. 2).

For oral group, 43.3% (45 cases) proceeded for normal delivery, 3.8% (4 cases) required LSCS intervention, and 2.9% (3 cases) required vacuum application for delivery.

For vaginal group, 41.3% (43 cases) proceeded for normal delivery, 6.7% (7 cases) required LSCS intervention, 1% (1 case) required forceps application for delivery, and 1% (1 case) required vacuum application for delivery.

Fig. 1 Distribution of number of doses

Table 1 Augmentation with syntocin

	Oral	Vaginal	Total
<i>Augmentation with syntocin</i>			
No			
Count	37	40	77
Total (%)	35.6	38.5	74.0
Yes			
Count	15	12	27
Total (%)	14.4	11.5	26.0
Total			
Count	52	52	104
Total (%)	50.0	50.0	100.0

Fig. 2 Distribution of mode of delivery

Induction to delivery interval				
Oral	52	808.42	323.536	0.845
Vaginal	52	795.62	343.664	

In oral group, mean induction to vaginal delivery interval was 13 h 43 min. Minimum induction to vaginal delivery interval was 5 h 15 min. Maximum induction to vaginal delivery interval was 26 h 15 min.

In vaginal group, mean induction to vaginal delivery interval was 13 h 26 min. Minimum induction to vaginal delivery interval was 4 h 16 min (Fig. 3).

Fig. 3 Distribution of colour of liquor

For oral group, 41.3% (43 cases) exhibited clear liquor, 5.8% (6 cases) exhibited thin MSAF, and 2.9% (3 cases) exhibited thick MSAF.

For vaginal group, 35.6% (37 cases) exhibited clear liquor, 4.8% (5 cases) exhibited thin MSAF, and 9.6% (10 cases) exhibited thick MSAF.

In oral group, there were three cases of thick MSL, and when compared to vaginal group, there were 10 cases. p value = 0.04 was significant. In oral group, out of 3 cases, 1 delivered normally, 1 case underwent vacuum-assisted delivery, and 1 case underwent LSCS. In vaginal group, out of 10 cases, 5 delivered normally, 1 case by vacuum-assisted delivery, 1 case by forceps, and 3 cases underwent LSCS.

For oral group, 1% (1 case) had nausea and vomiting and uterine hyperstimulation. A total of 3.8% (4 cases) had nausea and vomiting. In total, 1% (1 case) of mothers experienced uterine hyperstimulation.

For vaginal group, 2.9% (3 cases) mothers developed fever. 2.9% (3 cases) of mothers experienced uterine hyperstimulation, and p value is 0.14 which shows no significant difference.

Distribution of indication for LSCS

For oral group, 3.9% (4 cases) required emergency LSCS. Of the 4 cases, 3 cases were taken for LSCS due to failed induction. In total, 1 case was taken for LSCS due to thick meconium.

For vaginal group, 6.9% (7 cases) required emergency LSCS. Of the 7 cases, 1 case was taken for LSCS due to DTA, 3 cases were taken for LSCS due to foetal distress, and 3 cases were taken for LSCS for failed induction.

For oral group, mean 1 min score was 7.40. Mean 5 min score was 8.520. Six neonates (5.8% cases) had APGAR score <6 at 1 min. None of neonates had APGAR score <6 at 5 min.

For vaginal group, mean 1 min score was 7.21. Mean 5 min score was 8.42. Two neonates (1.9% cases) had

Fig. 4 Distribution of APGAR score at 5 min

Fig. 5 Distribution of NICU admissions

APGAR score <6 at 1 min. None of the neonates had APGAR <6 at 5 min. A total of 7.7% of cases (8 cases) had APGAR 7 at 5 min (p value = 0.004) (Figs. 4, 5).

Discussion

In terms of maternal outcome, mean number of doses for oral group is 2.73 and vaginal group is 3.04. In another study done by Khatri et al. [3] found that there was no difference in mean number of doses required for both oral and vaginal groups.

In oral group, mean induction to vaginal delivery interval was 13 h 43 min and in vaginal group interval is 13 h 26 min which was statistically not significant. The need for oxytocin augmentation in oral group was 15, and in vaginal group it was 12; however, this difference was also statistically not significant. In another study done by Khatri et al. [3] showed that although interval was earlier in oral group than vaginal group (group A – 15.5 and group B 15.03 h, respectively), it was statistically insignificant showing that both routes are equally efficacious. In another study done by Rasheed et al. [4] showed that the mean

induction to delivery interval was significantly shorter in the vaginal group compared with the oral group (13.5 vs. 20.6 h, $p < 0.010$). In a study done by Emmanuel et al. [5] showed that the vaginal route reduced the mean induction to delivery interval by four and half hours (20.7 ± 12.1 vs. 16.2 ± 10.4 ; mean difference 4.50, 95% CI 0.63–0.82; $p = 0.02$).

Both groups had equal number of failed inductions. Emergency LSCS done for foetal distress was more in vaginal group 2.9% compared to oral group which is 1% but difference was not statistically significant (p value -0.55). According to study done by Komala et al. [6], 94% of cases delivered vaginally in oral group and in vaginal group 86% of cases delivered.

Numbers of cases with fever and hyperstimulation were more with vaginal group, and nausea and vomiting were more in oral group although this difference is not statistically significant. Number of thick MSL in oral group was 3.2% as compared to vaginal group which is 10.7% which was statistically significant (p value -0.04). APGAR score at 5 min 7/10 was seen in 7.7% in vaginal group as compared to 0% in oral group which was also statistically significant (0.004). Numbers of NICU admissions were also more in vaginal group compared to oral group. This finding is consistent with previous studies done by Uludag et al. [7]; this was 16.7% cases in vaginal and 5.9%. Of cases in oral group had meconium-stained liquor. A study done by Khatri et al. [3] (compared 100 µg oral and 25 µg vaginal) showed similar results. In studies done by Komala et al. [6] and Deshmukh et al. [8], no difference was seen between both groups. Abbassi et al. [9] showed oral route was better with respect to treatment interval, and number of doses required.

Conclusion

Misoprostol in either oral or vaginal route has proven to be equally effective for inducing labour in women at term pregnancy. However, occurrence of lesser incidence of meconium-stained liquor and NICU admissions and fewer caesareans with better neonatal outcome in women induced with oral misoprostol outweighs its advantages over the vaginal misoprostol.

However, further studies are required to standardise the dosage for oral route of misoprostol for induction of labour. This study showed that oral route of misoprostol is equally efficacious as vaginal route with less neonatal complications making it more safe.

Compliance with Ethical Standards

Conflict of interest Both authors declare that they have no conflict of interest.

Human and Animal Right Statements All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with Helsinki Declaration 1975, as revised in 2008.

Ethical statement This study was approved by the institutional ethical committee.

Informed Consent Informed consent was obtained from all patients for being included in the study.

References

1. Cunningham FG, Leveno KJ, Bloom SL, et al. Williams obstetrics. In: Labour induction. 24th ed. McGraw Hill: New York; 2014. p. 523–4.
2. Arias F, Daftary SN, Bhide AG. Practical guide to high risk pregnancy and delivery. In: Bhide A, Arulkumaran S, editors. Abnormal labour and delivery. 3rd ed. Amsterdam: Elsevier; 2008. p 373–90.
3. Khatri R, Sharma J, Amatya A. Oral, vaginal misoprostol: which route for induction of term labor? *N J Obstet Gynaecol*. 2007;2(1):23–8.
4. Rasheed R, Alam AA, Younus SR. Oral versus vaginal misoprostol for labour induction. *J Pak Med Assoc*. 2007;57(8):404–7.
5. Emmaneul PC, Ugwu EO, Obi SN, et al. Oral versus vaginal misoprostol for induction of labor in Enugu, Nigeria. *Arch Gynaecol Obstetr*. 2015;291(3):537–44.
6. Komala K, Reddy M, Quadri IJ, et al. Comparative study of oral and vaginal misoprostol for induction of labour, maternal and fetal outcome. *J Clin Diag Res*. 2013;7(12):2866–969.
7. Uludag S, Salihoglu Saricali F, Madazli R, et al. A comparison of oral and vaginal misoprostol for induction of labor. *Eur J Obstet Gynecol Reprod Biol*. 2005;122(1):57–60.
8. Deshmukh VL, Yelikar KA, Waso V. Comparative study of efficacy and safety of oral versus vaginal misoprostol for induction of labour. *J Obstet Gynaecol*. 2013;63(5):321–4.
9. Abbassi RM, Sirichand P, Rizvi S. Safety and efficacy of oral versus vaginal misoprostol use for induction of labor at term. *J Coll Phys Surg Pak*. 2008;18(10):625–9.